James Whiteside, MD
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $779 and has fallen 94.9% since, to $40 in 2023. That places this record below the midpoint for neurology clinicians in ID, where the typical reported total is $1,243.
Across 67 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$258
- Novartis$120
- EMD Serono, Inc.$95
- AbbVie$64
- CSL Behring$52
- Acadia Pharmaceuticals Inc$48
- plus $443 from 15 others
What the payments were for
- Speaking & faculty fees$283%
- Food & beverage$1,04296%
- Education$111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 20 | $258 |
| Novartis | 8 | $120 |
| EMD Serono, Inc. | 5 | $95 |
| AbbVie(2 entities) | 3 | $64 |
| CSL Behring | 3 | $52 |
| Acadia Pharmaceuticals Inc | 2 | $48 |
| Genentech USA, Inc. | 3 | $44 |
| Teva Pharmaceuticals USA, Inc. | 3 | $44 |
| Sanofi | 2 | $37 |
| Lilly USA, LLC | 2 | $34 |
| Sunovion Pharmaceuticals Inc. | 2 | $34 |
| Bristol Myers Squibb | 2 | $32 |
| AstraZeneca | 2 | $32 |
| Amgen | 1 | $29 |
| Amneal Pharmaceuticals LLC | 2 | $29 |
| Acorda Therapeutics, Inc | 2 | $28 |
| Greenwich Biosciences, Inc. | 1 | $26 |
| Livanova USA, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $20 |
| Saol Therapeutics Inc. | 1 | $15 |
| Biogen | 1 | $15 |
How this compares
$1,082 in reported general payments places this provider in the 45th percentile of 59 neurology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 115 | $87,471 |
| AustedoDeutetrabenazine | 23 | $66,966 |
| Nurtec OdtRimegepant Sulfate | 12 | $14,569 |
| Emgality PenGalcanezumab-Gnlm | 13 | $13,569 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $12,397 |
| Emgality SyringeGalcanezumab-Gnlm | 14 | $10,502 |
| Dimethyl Fumarate | 48 | $8,945 |
| Pyridostigmine Bromide | 37 | $3,603 |
| Lacosamide | 21 | $3,573 |
| Levetiracetam | 145 | $3,548 |
| Mycophenolate Mofetil | 29 | $2,656 |
| Atorvastatin Calcium | 291 | $2,426 |
| Gabapentin | 57 | $1,246 |
| Prednisone | 90 | $716 |
| ClopidogrelClopidogrel Bisulfate | 59 | $625 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $44 | $66,96623 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil | $29 | $6,25966 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 59 neurology providers in Idaho.
Other neurology in Boise
- Sergei KashirnyBoise$20K
- Anant WadhwaBoise$6K
- Jackie WhitesellBoise$2K
- Brittany LovascioBoise$2K
- Benjamin StewartBoise$2K
- Matthew TechyBoise$2K
- Kelly BlockBoise$2K
- Thomas StrobelBoise$1K
- Lukas ClarkBoise$1K
- Daniel SimmonsBoise$729
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.